Search

Displaying results 2361 - 2370 of 10000 in total
  1. Drug

    Belantamab mafodotin

    go.drugbank.com/drugs/DB15719
    ApprovedInvestigationalWithdrawn

    In the meantime, belantamab mafodotin will be available for patients in the Risk Evaluation and Mitigation Strategy (REMS) program who can enrol in a compassionate use program. … [L44236] In July of 2025, belantamab mafodotin was approved by Health Canada for a similar indication, but for use in combination with either [Dexamethasone] and [Bortezomib] or [Dexamethasone] and [Pomalidomide

  2. Drug

    Praziquantel

    go.drugbank.com/drugs/DB01058
    ApprovedInvestigationalVet approved

    [A263201] The efficacy of praziquantel in treating parasitic flatworms infection with low cost (~US$0.20 drug cost to treat a child) makes it an integral to WHO's plan to eliminate schistosomiasis by 2030 … Praziquantel is a pyrazino-isoquinolein derivative from the thioxantonic group used as a broad anthelmintic spectrum.

  3. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Nylidrin is a peripheral vasodilator. … FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies.

  4. Drug

    Zilganersen

    go.drugbank.com/drugs/DB18161
    ApprovedInvestigational

    Zilganersen is a glial fibrillary acidic protein (GFAP)-directed antisense oligonucleotide used to treat Alexander disease. … [L64096] Alexander disease is caused by variants in the *GFAP* gene that lead to overproduction and toxic accumulation of GFAP in astrocytes, and dysfunction in astrocytes can over time damage neurons

  5. Drug

    Alpelisib

    go.drugbank.com/drugs/DB12015
    ApprovedInvestigational

    It works by selectively inhibiting class I PI3K p110α [A179203], which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival … To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests.

    Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitors, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  6. Drug

    mRNA-1345

    go.drugbank.com/drugs/DB18739
    ApprovedInvestigational

    mRNA-1345 is a nucleoside modified mRNA encoding the F-glycoprotein from RSV subtype A stabilized in its prefusion conformation.[L53393] It is the primary ingredient of the RSV vaccine mRESVIA. … mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older.

  7. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    [L10139] Following engraftment, it causes an increase in the production of HbF and a subsequent decrease in HbS. … Sickle cell disease (SCD) is a genetic disorder characterized by the production of abnormal sickle-shaped red blood cells (called hemoglobin S, HbS) that initiate a pathophysiology resulting in severe

    Synonyms: from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a
  8. Drug

    Bamlanivimab

    go.drugbank.com/drugs/DB15718
    ApprovedInvestigational

    Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. … it in collaboration with Eli Lilly and Company.

  9. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    It is produced through recombinant DNA technology in mammalian CHO cells. The drug has activity as a selective co-stimulation modulator with inhibitory activity on T lymphocytes. … Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each.

  10. Drug

    Medrogestone

    go.drugbank.com/drugs/DB09124
    ApprovedWithdrawn

    Medrogestone (INN), also known as 6,17α-dimethyl-6-dehydroprogesterone, is a progestational agent derived from 17-methylprogesterone. … It was conceived as an alternative for an orally effective contraceptive option.[A31526] It was developed by Ayerst, approved in Canada in 1969 and its current status is cancelled post-marketing.

    Mixtures: PRESOMEN 28 COMP 0.3/5MG, PRESOMEN 28 COMP 0.3/5MG